The transcriptomic profile shows the protective effects of celecoxib on cirrhotic splenomegaly

References

• Gan C, Cai Q, Tang C, et al. Inflammasomes and pyroptosis of liver cells in liver fibrosis. Front Immunol. 2022;13:896473. doi: 10.3389/fimmu.2022.896473.
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18(3):151–166. doi: 10.1038/s41575-020-00372-7.
   PubMed Web of Science ®Google Scholar
• Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–171. doi: 10.1016/j.jhep.2018.09.014.
   PubMed Web of Science ®Google Scholar
• Engelmann C, Clària J, Szabo G, et al. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol. 2021;75(Suppl. 1):S49–S66. doi: 10.1016/j.jhep.2021.01.002.
   PubMedGoogle Scholar
• Kashani A, Salehi B, Anghesom D, et al. Spleen size in cirrhosis of different etiologies. J Ultrasound Med. 2015;34(2):233–238. doi: 10.7863/ultra.34.2.233.
   PubMed Web of Science ®Google Scholar
• Nascimbene A, Iannacone M, Brando B, et al. Acute thrombocytopenia after liver transplant: role of platelet activation, thrombopoietin deficiency and response to high dose intravenous IgG treatment. J Hepatol. 2007;47(5):651–657. doi: 10.1016/j.jhep.2007.06.012.
   PubMed Web of Science ®Google Scholar
• Yongxiang W, Zongfang L, Guowei L, et al. Effects of splenomegaly and splenic macrophage activity in hypersplenism due to cirrhosis. Am J Med. 2002;113(5):428–431. doi: 10.1016/s0002-9343(02)01210-x.
   PubMed Web of Science ®Google Scholar
• Li L, Duan M, Chen W, et al. The spleen in liver cirrhosis: revisiting an old enemy with novel targets. J Transl Med. 2017;15(1):111. doi: 10.1186/s12967-017-1214-8.
   PubMedGoogle Scholar
• Liu H, Lee SS. The spleen is a player in portal hypertension. Exp Physiol. 2012;97(9):999–1000. doi: 10.1113/expphysiol.2012.064485.
   PubMed Web of Science ®Google Scholar
• Tang S, Huang Z, Jiang J, et al. Celecoxib ameliorates liver cirrhosis via reducing inflammation and oxidative stress along spleen–liver axis in rats. Life Sci. 2021;272:119203. doi: 10.1016/j.lfs.2021.119203.
   PubMed Web of Science ®Google Scholar
• Thai LH, Mahévas M, Roudot-Thoraval F, et al. Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine. 2016;95(48):e5098. doi: 10.1097/MD.0000000000005098.
   PubMed Web of Science ®Google Scholar
• Amin MA, el-Gendy MM, Dawoud IE, et al. Partial splenic embolization versus splenectomy for the management of hypersplenism in cirrhotic patients. World J Surg. 2009;33(8):1702–1710. doi: 10.1007/s00268-009-0095-2.
   PubMed Web of Science ®Google Scholar
• Bolognesi M, Merkel C, Sacerdoti D, et al. Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis. 2002;34(2):144–150. doi: 10.1016/s1590-8658(02)80246-8.
   PubMedGoogle Scholar
• Chen Y, Wang W, Wang H, et al. Rapamycin attenuates splenomegaly in both intrahepatic and prehepatic portal hypertensive rats by blocking mTOR signaling pathway. PLOS One. 2016;11(1):e0141159. doi: 10.1371/journal.pone.0141159.
   PubMed Web of Science ®Google Scholar
• Mejias M, Garcia-Pras E, Gallego J, et al. Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension. J Hepatol. 2010;52(4):529–539. doi: 10.1016/j.jhep.2010.01.004.
   PubMed Web of Science ®Google Scholar
• Wang D, Yin J, Dong R, et al. Inhibition of janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats. Dig Liver Dis. 2015;47(4):315–323. doi: 10.1016/j.dld.2014.12.017.
   PubMedGoogle Scholar
• Tang SH, Gao JH, Wen SL, et al. Expression of cyclooxygenase-2 is correlated with lncRNA-COX-2 in cirrhotic mice induced by carbon tetrachloride. Mol Med Rep. 2017;15(4):1507–1512. doi: 10.3892/mmr.2017.6161.
   PubMed Web of Science ®Google Scholar
• Lu YY, Gao JH, Zhao C, et al. Cyclooxygenase-2 up-regulates hepatic somatostatin receptor 2 expression. Sci Rep. 2018;8(1):11033. doi: 10.1038/s41598-018-29349-y.
   PubMedGoogle Scholar
• Gao JH, Wen SL, Yang WJ, et al. Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis. PLOS One. 2013;8(7):e69309. doi: 10.1371/journal.pone.0069309.
   PubMed Web of Science ®Google Scholar
• Wen SL, Gao JH, Yang WJ, et al. Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes. J Gastroenterol Hepatol. 2014;29(11):1932–1942. doi: 10.1111/jgh.12641.
   PubMed Web of Science ®Google Scholar
• Zhang L, Tai Y, Zhao C, et al. Inhibition of cyclooxygenase-2 enhanced intestinal epithelial homeostasis via suppressing beta-catenin signalling pathway in experimental liver fibrosis. J Cell Mol Med. 2021;25(16):7993–8005. doi: 10.1111/jcmm.16730.
   PubMed Web of Science ®Google Scholar
• Tai Y, Zhao C, Zhang L, et al. Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress. J Cell Mol Med. 2021;25(22):10389–10402. doi: 10.1111/jcmm.16968.
   PubMed Web of Science ®Google Scholar
• Gao JH, Wen SL, Tong H, et al. Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut–liver axis in rats. Am J Physiol Gastrointest Liver Physiol. 2016;310(11):G962–G972. doi: 10.1152/ajpgi.00428.2015.
   PubMed Web of Science ®Google Scholar
• Gao JH, Wen SL, Feng S, et al. Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats. Angiogenesis. 2016;19(4):501–511. doi: 10.1007/s10456-016-9522-9.
   PubMed Web of Science ®Google Scholar
• Ozer EK, Goktas MT, Kilinc I, et al. Celecoxib administration reduced mortality, mesenteric hypoperfusion, aortic dysfunction and multiple organ injury in septic rats. Biomed Pharmacother. 2017;86:583–589. doi: 10.1016/j.biopha.2016.11.102.
   PubMed Web of Science ®Google Scholar
• Su W, Tai Y, Tang SH, et al. Celecoxib attenuates hepatocyte apoptosis by inhibiting endoplasmic reticulum stress in thioacetamide-induced cirrhotic rats. World J Gastroenterol. 2020;26(28):4094–4107. doi: 10.3748/wjg.v26.i28.4094.
   PubMed Web of Science ®Google Scholar
• Orlando R, Lirussi F, Basso SM, et al. Splenomegaly as risk factor of liver cirrhosis. A retrospective cohort study of 2,525 patients who underwent laparoscopy. In Vivo. 2011;25(6):1009–1012.
   PubMedGoogle Scholar
• Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362(9):823–832. doi: 10.1056/NEJMra0901512.
   PubMed Web of Science ®Google Scholar
• Asanoma M, Ikemoto T, Mori H, et al. Cytokine expression in spleen affects progression of liver cirrhosis through liver-spleen cross-talk. Hepatol Res. 2014;44(12):1217–1223. doi: 10.1111/hepr.12267.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective. Curr Top Med Chem. 2005;5(5):443–448. doi: 10.2174/1568026054201695.
   PubMed Web of Science ®Google Scholar
• Lee YC, Chang CH, Lin JW, et al. Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. Liver Int. 2012;32(5):859–866. doi: 10.1111/j.1478-3231.2011.02739.x.
   PubMed Web of Science ®Google Scholar
• Clària J, Kent JD, López-Parra M, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology. 2005;41(3):579–587. doi: 10.1002/hep.20595.
   PubMed Web of Science ®Google Scholar
• Lewis SM, Williams A, Eisenbarth SC. Structure and function of the immune system in the spleen. Sci Immunol. 2019;4(33):eaau6085. doi: 10.1126/sciimmunol.aau6085.
   PubMed Web of Science ®Google Scholar
• Helming L. Inflammation: cell recruitment versus local proliferation. Curr Biol. 2011;21(14):R548–R550. doi: 10.1016/j.cub.2011.06.005.
   PubMed Web of Science ®Google Scholar
• Lan T, Qian S, Tang C, et al. Role of immune cells in biliary repair. Front Immunol. 2022;13:866040. doi: 10.3389/fimmu.2022.866040.
   PubMed Web of Science ®Google Scholar
• Klatka J, Grywalska E, Hymos A, et al. Cyclooxygenase-2 inhibition enhances proliferation of NKT cells derived from patients with laryngeal cancer. Anticancer Res. 2017;37(8):4059–4066. doi: 10.21873/anticanres.11791.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang X, Luo L, et al. Adipocyte-derived PGE2 is required for intermittent fasting-induced Treg proliferation and improvement of insulin sensitivity. JCI Insight. 2022;7(5):e153755. doi: 10.1172/jci.insight.153755.
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Kawanaka H, Yoshida D, et al. Splenic hemodynamics and decreased endothelial nitric oxide synthase in the spleen of rats with liver cirrhosis. Life Sci. 2007;80(22):2036–2044. doi: 10.1016/j.lfs.2007.03.009.
   PubMed Web of Science ®Google Scholar
• Cesta MF. Normal structure, function, and histology of the spleen. Toxicol Pathol. 2006;34(5):455–465. doi: 10.1080/01926230600867743.
   PubMed Web of Science ®Google Scholar
• Son G, Hines IN, Lindquist J, et al. Inhibition of phosphatidylinositol 3-kinase signaling in hepatic stellate cells blocks the progression of hepatic fibrosis. Hepatology. 2009;50(5):1512–1523. doi: 10.1002/hep.23186.
   PubMed Web of Science ®Google Scholar
• Gao J, Wei B, de Assuncao TM, et al. Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis. J Hepatol. 2020;73(5):1144–1154. doi: 10.1016/j.jhep.2020.04.044.
   PubMed Web of Science ®Google Scholar
• Zhang CY, Tan XH, Yang HH, et al. COX-2/sEH dual inhibitor alleviates hepatocyte senescence in NAFLD mice by restoring autophagy through Sirt1/PI3K/AKT/mTOR. Int J Mol Sci. 2022;23(15):8267. doi: 10.3390/ijms23158267.
   PubMed Web of Science ®Google Scholar